Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating reissued by Cantor Fitzgerald in a research note issued on Wednesday. They presently have a $60.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 19.52% from the stock’s current price.
The analysts wrote, “On Wednesday, December 13, we hosted a series of investor meetings with Omnicell’s CFO, Peter Kuipers.””
Other analysts have also issued research reports about the company. Craig Hallum reiterated a “buy” rating and issued a $62.00 price target (up previously from $52.00) on shares of Omnicell in a report on Monday, October 30th. Oppenheimer reiterated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a report on Thursday, October 19th. Benchmark upped their target price on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Finally, Zacks Investment Research lowered Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $55.14.
Shares of Omnicell (NASDAQ OMCL) opened at $50.20 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53. Omnicell has a twelve month low of $31.85 and a twelve month high of $55.40.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.42. The firm had revenue of $186.78 million during the quarter, compared to analyst estimates of $192.45 million. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. Omnicell’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.40 earnings per share. equities research analysts predict that Omnicell will post 0.12 EPS for the current fiscal year.
In other Omnicell news, VP Peter J. Kuipers sold 4,724 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the completion of the sale, the vice president now owns 40,544 shares in the company, valued at $1,935,570.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Jorge R. Taborga sold 6,295 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $48.69, for a total value of $306,503.55. Following the sale, the vice president now owns 50,013 shares of the company’s stock, valued at approximately $2,435,132.97. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,164 shares of company stock valued at $1,410,666. 3.77% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Turner Investments LLC purchased a new stake in shares of Omnicell during the 2nd quarter valued at $181,000. Flinton Capital Management LLC lifted its holdings in shares of Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock valued at $182,000 after purchasing an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in shares of Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after purchasing an additional 1,830 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Omnicell by 36.4% during the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock valued at $200,000 after purchasing an additional 1,242 shares during the last quarter. Finally, Pinebridge Investments L.P. lifted its holdings in shares of Omnicell by 1.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock valued at $211,000 after purchasing an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2017/12/15/omnicell-omcl-stock-rating-reaffirmed-by-cantor-fitzgerald.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.